Frazier Life Sciences Public Fund Reports 5.9% Stake In Q32 Bio, 1,755,116 Shares
A Schedule 13G lists the fund's position, plus two sister Frazier funds holding 0.1% and 0.4%, with an October 2 trigger date.
Frazier Life Sciences Public Fund, L.P. holds 1,755,116 shares of Q32 Bio, or 5.9% of its common stock, according to a Schedule 13G filed with the SEC on Friday. The 13G is a passive ownership disclosure, filed by investors who say they are not seeking control.
What the Schedule 13G shows
The filing gives October 2 as the date of the event that triggered the report. The public fund holds the shares directly, and the filing lists shared voting power over all of them, with none held as sole voting power.
Two other Frazier vehicles joined the filing. Frazier Life Sciences XI, L.P. holds 23,029 shares, or 0.1% of the class, and Frazier Life Sciences XII, L.P. holds 125,039 shares, or 0.4%.
Each fund is listed alongside its general partner entities. The filing says each fund's general partner is managed by an investment committee that acts by majority vote: four members for the public fund, three each for XI and XII. It states that no committee member is attributed beneficial ownership of the shares the fund holds directly.
The filer also says the filing is not an admission that any reporting person is a beneficial owner of the securities or part of a group with another person.
What it changes for Q32 Bio holders
The disclosure puts a named holder above the 5% line in the stock. The filer certified that the shares were not acquired and are not held to change or influence control of Q32 Bio.
Q32 Bio had a market capitalization of $241 million, according to market data. At Friday's close the stock was $8.34, up 3.09%, and it traded at $8.00 in Friday after-hours trading.
The filing lists the reporting persons' address as c/o Frazier Life Sciences Management, L.P. in Palo Alto, California, and Q32 Bio's as Waltham, Massachusetts.
